ClinicalTrials.gg
Active, not recruitingNCT06643728Updated May 26, 2026

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

A Phase 2 interventional study of Bimagrumab and Tirzepatide in Obesity and Overweight, sponsored by Eli Lilly and Company. Active, not recruiting at 12 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
28th of 104
252 · median 69
Started
2024
with 9 others
Phase 2
22 of 104
14 open now
Primary completion
2026-01
later than 0 of 78 live
Registered
32nd of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 28th largest by enrollment, is one of 10 that started in 2024, is one of 22 in phase 2, reaches primary completion later than 0 of the 78 other live ones, and was the 32nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Muscle
  • Lean
  • Fat
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a of

    • ≥30 kilograms per square meter (kg/m2) or
    • ≥27 kg/m2 and \<30 kg/m2, with at least one of the following weight-related comorbidities:

      • Hypertension
      • Dyslipidemia
      • Cardiovascular disease
      • Obstructive sleep apnea
  • Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)

Exclusion criteria

Exclusion Criteria:

  • Have a prior or planned surgical treatment for obesity
  • Have at least one laboratory value suggestive of diabetes during screening
  • Use of metformin, or any other glucose-lowering medications
  • Have Type 1 Diabetes, latent diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma
  • Have poorly controlled hypertension
  • Have any of the following cardiovascular conditions within 3 months prior to screening:

    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • unstable angina, or
    • hospitalization due to congestive heart failure
  • Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
  • Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
  • Have a history of (NYHA) Functional Classification III or IV congestive heart failure
  • Have a history of symptomatic gallbladder disease within the past 2 years
  • Have signs and symptoms of any liver disease
  • Have a disease or condition known to cause gastrointestinal malabsorption or a known gastric emptying abnormality
  • Have a history of acute or chronic pancreatitis
  • Have renal impairment, measured as estimated \<30 mL/minute/1.73 m2
  • Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Part A: Bimagrumab Dose 2 + Tirzepatide Placebo

    Participants will receive bimagrumab subcutaneously (SC) and tirzepatide placebo SC

    Drug: Bimagrumab · Drug: Tirzepatide Placebo

  • Active comparator
    Part A: Bimagrumab Placebo + Tirzepatide Dose 1

    Participants will receive bimagrumab placebo SC and tirzepatide SC

    Drug: Tirzepatide · Drug: Bimagrumab Placebo

  • Active comparator
    Part A: Bimagrumab Placebo + Tirzepatide Dose 2

    Participants will receive bimagrumab placebo SC and tirzepatide SC

    Drug: Tirzepatide · Drug: Bimagrumab Placebo

  • Experimental
    Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1

    Participants will receive bimagrumab SC and tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Experimental
    Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2

    Participants will receive bimagrumab SC and tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Experimental
    Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2

    Participants will receive bimagrumab SC and tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Placebo comparator
    Part A: Bimagrumab Placebo + Tirzepatide Placebo

    Participants will receive bimagrumab placebo SC and tirzepatide placebo SC

    Drug: Bimagrumab Placebo · Drug: Tirzepatide Placebo

  • Experimental
    Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1

    Participants will receive bimagrumab SC and tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Experimental
    Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1

    Participants will receive bimagrumab SC and tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Experimental
    Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1

    Participants will receive bimagrumab SC and tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Experimental
    Part B: Bimagrumab Dose 1 + Tirzepatide Placebo

    Participants will receive bimagrumab SC and tirzepatide placebo SC

    Drug: Bimagrumab · Drug: Tirzepatide Placebo

  • Placebo comparator
    Part B: Bimagrumab Placebo + Tirzepatide Placebo

    Participants will receive bimagrumab placebo SC and tirzepatide placebo SC

    Drug: Bimagrumab Placebo · Drug: Tirzepatide Placebo

Interventions

  • Administered SC

    Also known as: LY3985863, BYM338, VER201

  • Administered SC

    Also known as: LY3298176

  • DrugBimagrumab Placebo

    Administered SC

  • DrugTirzepatide Placebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percent Change from Baseline in Total Body Fat Mass by Dual-Energy X-Ray Absorptiometry (DXA)

    Time frame: Baseline, Week 24, Week 48

  2. Change from Baseline in Body Weight

    Time frame: Baseline, Week 24, Week 48

  3. Percentage of Participants Achieving ≥5% Body Weight Reduction

    Time frame: Baseline, Week 24, Week 48

  4. Percentage of Participants Achieving ≥10% Body Weight Reduction

    Time frame: Baseline, Week 24, Week 48

  5. Percentage of Participants Achieving ≥15% Body Weight Reduction

    Time frame: Baseline, Week 24, Week 48

  6. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 24, Week 48

  7. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 24, Week 48

  8. Change from Baseline in Waist-to-Height Ratio (WHtR)

    Time frame: Baseline, Week 24, Week 48

  9. Percent Change from Baseline in Visceral Adipose Tissue (VAT)

    Time frame: Baseline, Week 24, Week 48

  10. Percent Change from Baseline in Total Body Lean Mass by DXA

    Time frame: Baseline, Week 24, Week 48

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jan 2026, 14 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 14 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 16, 2024
StartActual
Oct 21, 2024
Primary completionActual
Jan 16, 2026
CompletionEst.
Jan 2027
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06643728
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Oct 21, 2024
Primary completion
Jan 16, 2026
Completion
Jan 2027 (estimated)
Last update
May 26, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bimagrumab · Tirzepatide

Start the discussion